Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSven De PourcqUniversity of SienaETElena TofacchiUniversity of FlorenceMRMarco Gabriele RaddiUniversity of Siena

Discussion

Loading...

Member takes

Overview

Analysis identifies distinct inflammatory subgroups in lower-risk MDS with varied response to ESAs, suggesting implications for treatment.

Key Points

  • To characterize inflammatory profiles and their relation to treatment responses in lower-risk myelodysplastic syndromes (MDS).
  • Assessed 36 serum analytes in 95 lower-risk MDS cases at diagnosis.
  • Utilized principal component analysis and k-means clustering to stratify distinct subgroups.
  • Employed random forest models to identify key discriminatory cytokines among clusters.
  • Identified five distinct inflammatory subgroups in lower-risk MDS.
  • IL-1β, IL-2, and IL-17E were among the most discriminatory cytokines.
  • Clustering revealed varying responses to erythropoietin stimulating agents, with significant implications for patient management.

Cite This Study

Pourcq et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d83ahttps://doi.org/10.1182/blood-2025-3866
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inflammatory profile of lower risk myelodysplastic syndromes2024 · 17 citations
  2. 2Immunological biomarkers and TARC/CCL17 in myelodysplastic syndrome: Insights into immune microenvironment regulation2025
  3. 3Real-world patient characteristics, treatment patterns, and outcomes in patients with myelodysplastic syndromes2025
  4. 4Association between lymphocyte-associated ratios, C-reactive protein and prognostic value in myelodysplastic syndromes2025 · 2 citations
  5. 5A prognostic model integrating disease‑ and patient‑oriented factors identifies poor‑outcome patients with low‑risk MDS: A multicenter real‑world cohort study (KOTOSG)2025